Provided by Tiger Trade Technology Pte. Ltd.

Fidelity MSCI Health Care Index ETF

81.12
+0.52000.65%
Volume:118.11K
Turnover:9.55M
Market Cap:3.52B
PE:- -
High:81.13
Open:80.53
Low:80.42
Close:80.60
52wk High:85.46
52wk Low:67.77
Shares:43.35M
Float Shares:43.35M
Volume Ratio:0.36
T/O Rate:0.27%
Dividend:1.02
Dividend Rate:1.25%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Cigna: Announces Exclusive Agreement with UnitedHealth Global to Endorse Ghb as Preferred International Health Insurer - Website

THOMSON REUTERS
·
Sep 29

Cigna Global Health Benefits Signs Exclusive Endorsement Deal with UnitedHealthcare Global

Reuters
·
Sep 29

Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium

MT Newswires Live
·
Sep 29

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 29

J&J : Bofa Global Research Raises Price Objective to $278 from $263

THOMSON REUTERS
·
Sep 29

AbbVie Partners with Valkai to Deploy AI Across Clinical Development

Reuters
·
Sep 29

Abbvie - to Deploy AI Via Valkai Partnership to Improve Clinical Research Efficiency

THOMSON REUTERS
·
Sep 29

Abbvie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

THOMSON REUTERS
·
Sep 29

Allergan Aesthetics Receives Health Canada Authorization for Boey® (Trenibotulinumtoxine), the First and Only Rapid-Onset, Short-Duration Neurotoxin for Frown Lines

THOMSON REUTERS
·
Sep 29

J&J Says Imaavy Shows Sustained Disease Control Through Two Years in Adolescent Myasthenia Gravis Study

Reuters
·
Sep 29

J&J - no New Safety Signals Identified Through Two Years of Imaavy Treatment

THOMSON REUTERS
·
Sep 29

J&J - Presents New Data on Imaavy in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

J&J - Two-Year Phase 2/3 Data Shows Sustained Disease Control and Reduced Corticosteroid Use in Adolescents

THOMSON REUTERS
·
Sep 29

Eli Lilly Reports Zepbound Showed 4.5% Greater Weight Loss Than Novo Nordisk's Wegovy HD

MT Newswires Live
·
Sep 29

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 29

Eli Lilly’s Zepbound shows improved weight loss vs. Wegovy in new analysis

TIPRANKS
·
Sep 29

Eli Lilly - Zepbound 10 Mg and 15 Mg Show Comparable Adverse Event Discontinuation Rates to Wegovy Hd

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Shows 4.5% Greater Weight Loss than Wegovy Hd in Adults with Obesity

THOMSON REUTERS
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound Achieves 20.2% Weight Reduction vs 13.7% for Wegovy at 72 Weeks

THOMSON REUTERS
·
Sep 29